Johnson & Johnson raises 2026 sales outlook to 6.7%-7.1% while projecting $100.7B midpoint revenue
Johnson & Johnson raises 2026 sales outlook to 6.7%-7.1% while projecting $100.7B midpoint revenue（摘要待生成）
Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up - Yahoo Finance
Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up - Yahoo Finance（摘要待生成）
Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit - Yahoo Finance
Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit - Yahoo Finance（摘要待生成）
Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up? - Yahoo Finance
Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up? - Yahoo Finance（摘要待生成）
Johnson & Johnson outlook: bull and bear cases after Q3 earnings
Johnson & Johnson outlook: bull and bear cases after Q3 earnings（摘要待生成）
J&J (JNJ) Q3 2026 Earnings Call Transcript
J&J (JNJ) Q3 2026 Earnings Call Transcript（摘要待生成）
Johnson &Johnson Stock Earnings: Can a Spinoff Fix Its Medtech Problem - Barron's
Johnson &Johnson Stock Earnings: Can a Spinoff Fix Its Medtech Problem Barron's
Johnson & Johnson reports response rate for head, neck cancer treatment
Johnson & Johnson reports response rate for head, neck cancer treatment（摘要待生成）
8 Of 11 Sectors Fall In Thursday Trading As Energy Leads
Three sectors are higher and eight are lower in Thursday's regular session, with the top three split across cyclical, defensive and growth groups. The leaders are separated rather than clustered, with Energy clearly ahead of the next sectors in the ranking.
强生公布数据称 其药物Rybrevant Faspro在头颈部鳞状细胞癌（HNSCC）的一线治疗中取得了77%的客观缓解率（ORR）
强生公布数据称 其药物Rybrevant Faspro在头颈部鳞状细胞癌（HNSCC）的一线治疗中取得了77%的客观缓解率（ORR）（摘要待生成）
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.（摘要待生成）
Johnson & Johnson 8-K (2.02, 9.01): reported results of operations
Johnson & Johnson reported third-quarter 2026 sales of $25.4 billion, up 5.9%, and diluted EPS of $0.09; adjusted EPS was $2.59, and it raised its 2026 guidance, projecting $101.2 billion in reported sales and adjusted EPS of $11.10.
Johnson & Johnson Announces New Two-year Results From Its Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE In Adults With Moderate-To-Severe Plaque Psoriasis; Data Demonstrated Consistently High Levels Of Skin Clearance And Patient-Reported Symptom Improvement At Week 112, With No New Safety Signals
Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times
Johnson & Johnson ICOTYDE long-term data show two-year psoriasis results
On October 9, 2026, J&J reported Phase 3 data presented at Fall Clinical Dermatology: nearly three-quarters of adults and adolescents achieved clear or almost clear skin at two years, with a continued favorable safety profile.
BofA raises J&J price target to $282 from $278
On Oct. 9, 2026, Bank of America Securities analyst Jason Gerberry raised his target to $282 from $278 and maintained Hold. J&J shares closed at $261.44, up 1.93% that day; the page did not attribute the move to the analyst action.